title: Species differences in platelet responses to thrombin and SFLLRN. receptor-mediated calcium mobilization and aggregation, and regulation by protein kinases.
abstract: The thrombin receptor on human platelets is activated by thrombin to stimulate platelet aggregation through the tethered ligand SFLLRN. This study examined the effects of thrombin and SFLLRN on aggregation and calcium mobilization ([Ca2+]i) in rat, guinea pig, rabbit, dog, monkey, and human platelets, and the role of protein kinases in regulating these functions. Thrombin induced platelet aggregation and [Ca2+]i in all species studied; however, only guinea pig, monkey and human platelets were responsive to SFLLRN. Similar species specific effects were obtained with [Ca2+]i studies. The kinetic profile for [Ca2+]i differed among species, suggesting that regulatory mechanisms for calcium differed between agonists and among species. Staurosporine, a non-selective inhibitor of protein kinases, inhibited platelet aggregation induced by thrombin or SFLLRN in all species. Staurosporine inhibited thrombin-induced [Ca2+]i in guinea pigs, had no effect in rat, and increased [Ca2+]i in all other species. Staurosporine inhibited SFLLRN-induced [Ca2+]i in guinea pig, yet had no effect in monkey or human. Tyrphostin 23, a specific inhibitor of tyrosine protein kinases, inhibited thrombin-induced aggregation of rabbit, monkey, dog and human platelets. SFLLRN-induced aggregation was also inhibited by tyrphostin 23. Tyrphostin 23 inhibited [Ca2+]i induced by either thrombin or SFLLRN in all species. Based on the differential response to agonist stimulation, we propose that thrombin can activate platelets via SFLLRN-dependent and independent mechanisms, which could involve yet unrecognized subtypes of the thrombin receptor or distinct cellular activating mechanisms. Furthermore, differential regulation of calcium mobilization and aggregation was observed in those platelets responding to either thrombin or SFLLRN.
authors.affiliation: Drug Discovery Research, The R. W. Johnson Pharmaceutical Research Institute Spring House, PA 19477, USA.
authors.forename: C K
authors.initials: CK
authors.lastname: Derian
authors.forename: R J
authors.initials: RJ
authors.lastname: Santulli
authors.forename: K A
authors.initials: KA
authors.lastname: Tomko
authors.forename: B J
authors.initials: BJ
authors.lastname: Haertlein
authors.forename: P
authors.initials: P
authors.lastname: Andrade-Gordon
mesh_terms: D000818:Animals; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology*; D020013:Calcium Signaling / Q000187:drug effects; D004285:Dogs; D005260:Female; D006168:Guinea Pigs; D006801:Humans; D008252:Macaca fascicularis; D008297:Male; D010446:Peptide Fragments / Q000494:pharmacology*; D010974:Platelet Aggregation / Q000187:drug effects; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D011494:Protein Kinases / Q000502:physiology; D011817:Rabbits; D051381:Rats; D020318:Rats, Long-Evans; D013045:Species Specificity; D019311:Staurosporine / Q000494:pharmacology; D013917:Thrombin / Q000494:pharmacology*; D020032:Tyrphostins / Q000494:pharmacology
chemical_list: D010446:Peptide Fragments; D047428:Protein Kinase Inhibitors; D020032:Tyrphostins; C082835:thrombin receptor peptide (42-47); D011494:Protein Kinases; D013917:Thrombin; D019311:Staurosporine; C060641:tyrphostin A23